Nov. 2016. Wondaleaf was showcased to UNFPA officials in a conference at United Nation in Bangkok. The pivotal meeting also led to Wondaleaf’s clinical trial in South Africa in 2017. The functional performance study conducted by MatCH has now been completed. The favourable results will be published in due course.
Posts by :
The story of Wondaleaf is told in an international film documentary on innovative female condoms. We are privileged to be interviewed and glad to have the opportunity to make the new invention known to more people.
Joyride is a 1 hour documentary written and produced by Randall Wood in partnership with Screen Australia, ZDF/ARTE and other major broadcasters.
June 2017. In addition to the grants from PlatCOM Venture Sdn Bhd of Agensi Innovasi Malaysia (RM 700,000) and Cradle Fund Sdn Bhd of Ministry of Finance (RM 500,000), Twin Catalyst Sdn Bhd is honored to receive about RM 1,800,000 grant from Ministry of Science, Technology and Innovation for continuing the work on Wondaleaf. The generous grants showed the Malaysian government’s commitment to encouraging innovations in the country.
Twin Catalyst is committed to further develop and improve Wondaleaf to showcase to the world. Follow us on our social media pages to keep updated on further developments.
This release is current as of 20.12.2017.
According to World Health Organization, annually the world has 86 million unintended pregnancies and a maternal mortality of 287,000 women, with unsafe abortion accounting for a high percentage of maternal deaths. An estimated 222 million women wish to delay or space their pregnancies but do not have access to modern contraceptives. On top of this, there are 499 million new sexually transmitted infections (STIs) occurring each year. In 2011, an estimated 2.5 million people became newly infected with HIV, with heterosexual contact as one of the primary modes of transmission.
With an ever-increasing prevalence of unintended pregnancies and STIs, the world is in urgent need of a contraceptive method that can be completely preventive of the above, while at the same time affordable and user-friendly.
Invented and patented by a gynecologist in Malaysia, Wondaleaf may be the answer to such needs, as shown by successful testing of working and functional prototypes.
Wondaleaf is an ultra-thin (of 0.02 to 0.025 mm) waterproof polyurethane female condom that has an extended adhesive shield covering the entire external genitalia to prevent direct skin contact and exchange of body fluid between sexual partners during intercourse, thereby providing potentially 100% protection against unintended pregnancies and STIs.
Chemically inert Polyurethane film has long been used in both male and female condom industries. It is stronger, thinner and provides better tactile and heat transfers than latex or nitrile used in standard condoms and female condoms.
Wondaleaf is designed to be easily deployed on a female user within seconds. Like 3M’s Tegaderm transparent film wound dressing, it is light and flexible, thus allowing Wondaleaf to be worn at any time before coitus and removed any time after that, both at the convenience of the user. The waterproof adhesive shield can block out unpleasant vaginal or anal discharges and menstruation from within, and contaminants and soiling from outside, therefore freeing the users from biological and environmental restrictions in sexual activities. In addition to these, the shield can be coloured, perfumed or flavoured to enhance the user’s look and appeal.
For women, Wondaleaf gives them the empowerment they badly need in the prevention of pregnancies and STIs. For men, Wondaleaf avoids the loss of sensation associated with condom and the need of maintaining erection to keeping condom in place. Furthermore, if the men so wish, they can turn Wondaleaf into a male condom that comes with an extended protective shield by simply inverting the condom portion of Wondaleaf.
One of the most important aspects of Wondaleaf however lies in the fact that it is totally and immediately reversible contraception, it does not require medical consultations and interventions, and it is essentially free of contraindications and side effects. None of the currently available contraceptive methods is able to fulfil all these criteria of an ideal contraception.
Just like surgeries are now performed with gloved hands; in years to come, it will be both unsavoury and reckless for anyone to have sexual intercourse without wearing a comprehensive protective barrier such as Wondaleaf.
Wondaleaf is currently undergoing clinical trials with the aim of establishing its efficacy as a barrier contraceptive, and its utility in menstrual control. These trials further have the aim of establishing the acceptability and usability of this device, and will be used in the Malaysian Device Authority, US Food and Drug Agency, Australian Therapeutic Goods Administration and other regulatory agency device approval processes.
The clinical trial to assess the performance of Wondaleaf® as a female barrier contraceptive method among healthy volunteer married couples is conducted by Clinical Research Centre of Sibu Hospital, led by A/Prof. Dr Toh Teck Hock and Dato Dr Ong Loke Meng. The study also aims to determine the acceptability and satisfaction of use of Wondaleaf® by subjects and their spouses, as well as its safety profile. The study has been approved by the Medical Research and Ethics Committee of the Ministry of Health Malaysia (NMRR-15-333-24953), and registered on the ClinicalTrials.gov (NCT02593214). For more information about this study, please contact Ms Yap Ling of Clinical Research Centre, Sibu Hospital at 084-314569 or email her at email@example.com,.
Trial protocols for ongoing trials are summarised below
On the 5th of February, 2015, the founder of Twin Catalyst and inventor of Wondaleaf, Dr. John Tang Ing Ching signed a Memorandum of Understanding (MOU) with the University College of Technology Sarawak (UCTS).
The signing of the MOU signified Twin Catalyst’s first big step forward of many towards a closer partnership with local resources and agencies. The partnership promises further research and development in the field of Mechanical and Manufacturing Engineering; combining medical experience with technical and engineering expertise. The signing of the MOU also opens up local post-graduate research opportunities in an innovative and exciting area of study.
The ceremony was attended by several influential individuals, including the director of the Centre of Quality Assurance, Prof. Datin Dr. Napsian Ismail, and the director of the Centre of Industrial Linkages & Entrepreneurial Development (iLED, Dr. Thoman Moh Shan Yau. Speeches were also given by the Deputy Vice-Chancellor of UCTS, Prof. Dato’ Dr Sarabudin Mohd; and Assistant Minister of Public Health Sarawak, YB Datuk Dr. Jerip Susil.
View more here